More studies are needed to address the variability in CK19 mRNA expression in PCa, as well as to consider the possibility of analyzing other PCa-specific biomarkers, such as PSMA [27], either alone or in combination with CK19. The gene discussed is FOLH1; the disease is posterior cortical atrophy.